학술논문
EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy.
Document Type
Article
Source
Subject
*DIFFUSE large B-cell lymphomas
*RITUXIMAB
*COST effectiveness
*B cells
*MYC oncogenes
*
*
*
*
Language
ISSN
1098-3015